Bluechiip Limited Stock Market Press Releases and Company Profile
Half-Year Financial Report
Half-Year Financial Report

Melbourne, Feb 25, 2020 AEST (ABN Newswire) - The principal activity of Bluechiip Ltd (googlechartASX:BCT) during the half year was the development and commercialisation of a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries which represents a generational change from current methods such as labels (hand-written and pre-printed), barcodes (linear and 2D) and microelectronic integrated circuit (IC)-based RFID (Radio Frequency Identification).

Bluechiip's cash receipts are solid and we have made significant progress on our chip delivery. We are currently delivering tens of thousands of chips a month, progressing to 100,000 a month, then over 200,000 a month to deliver 3 to 5 million chips a year. We continue to invest in research & development on our chips, to improve both quality and efficiency of chip delivery. We experienced some delay in chip delivery towards the end of the calendar year, but our supply of chips is now strong to our existing customers including Labcon. We have 35 developer kids in the market place, and are well positioned to convert these into clients. We continue to work hard on our quality processes - including ISO 9001.

To view Half Yearly Report, please visit:
https://abnnewswire.net/lnk/U9B015L5


About Bluechiip Limited

Bluechiip Ltd ASX BCTBluechiip Ltd (ASX:BCT) understands that every sample - stem cells, blood, eggs, sperm and other biospecimens - is critical, so our objective is to manage each one with optimal quality in the most efficient way. Bluechiip's advanced management solution is the only one that provides sample temperature with ID in cryogenic environments to. Most importantly, this delivers confidence in every sample.

Bluechiip's unique patented technology is a MEMS-based wireless tracking solution that contains no electronics. It represents a generational change from current tracking methods such as labels (hand-written and pre-printed), barcodes (linear and 2D), and Radio Frequency Identification. Bluechiip tags are either embedded or manufactured into storage products such as vials or bags. Each product can be easily identified, and critical information such as sample temperature, is detected by readers and stored in the Bluechiip software. In addition to functioning in extreme temperatures, the Bluechiip(R) Advanced Sample management solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

Bluechiip's technology has applications in healthcare, including in cryogenic storage facilities (biobanks and biorepositories), pathology, clinical trials and forensics. Other key markets include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Bluechiip: Delivering confidence in every sample.

 

https://twitter.com/bluechiip https://www.youtube.com/channel/UCaVcyO4O2oJ_9fLdMs6JIyQ https://www.linkedin.com/company/bluechiip-limited abnnewswire.com 


Contact

Corporate enquiries
Andrew McLellan
Managing Director - CEO
Ph: +61-457-823-470
andrew.mclellan@bluechiip.com

Media
Richard Allen
Ph: +61-3-9915-6341
Oxygen Financial PR
richard@oxygenpr.com.au



ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 8) (Last 30 Days: 26) (Since Published: 2332)